{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:34:47Z","timestamp":1768070087843,"version":"3.49.0"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T00:00:00Z","timestamp":1229558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory. Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg\u2010Doxo) in primary cutaneous T\u2010cell lymphomas, while in primary cutaneous B\u2010cell lymphomas (PCBCLs), the drug efficacy has never been assessed so far.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> We performed a prospective phase II pilot clinical trial of Peg\u2010Doxo monotherapy (20\u2003mg\/m<jats:sup>2<\/jats:sup>) in PCBCLs. One patient had a marginal zone B\u2010cell lymphoma and four were affected by diffuse large B\u2010cell lymphoma\u2010leg type, all with widespread nodular lesions.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> All the patients achieved a complete response (CR\u2003=\u2003100%) in a short period of time (median 3\u2003months), even when pretreated with radio\u2010chemotherapy. Two experienced a relapse. At follow\u2010up, one patient died for progressive disease; four are in CR after 5, 52, 63 and 69\u2003months. As concerning the toxicity profile, the treatment was well\u2010tolerated, no one decreased or delayed the dose. The haematological toxicity was mild with only one case of grade III neutropenia; a patient showed a grade I neurotoxicity. Dermatological toxicity, in particular the palmar\u2013plantar erythrodysesthesia, did not occurred, probably because of both the low dosages of Peg\u2010Doxo monotherapy and the oral prophylaxis with pyridoxine.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> In spite of the small number of patients, it emerges that monochemotherapy with Peg\u2010Doxo has a significantly high clinical activity and a good safety profile in PCBCLs, even in aggressive forms, compared with other therapeutic regimens, which are completely reviewed. It suggests the need of further investigations in this field.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01197.x","type":"journal-article","created":{"date-parts":[[2008,12,19]],"date-time":"2008-12-19T19:32:47Z","timestamp":1229715167000},"page":"184-193","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B\u2010cell lymphomas and comparison with the commonly used therapies"],"prefix":"10.1111","volume":"82","author":[{"given":"Stefano","family":"Pulini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Rupoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Goteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Alterini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberta","family":"Bettacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Mulattieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Tassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Scortechini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fioritoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.053413"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.Supplement-1.94"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.004"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:1:55"},{"key":"e_1_2_6_7_2","first-page":"822","article-title":"Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B\u2010cell lymphoma: results from a prospective phase II study","volume":"87","author":"Martino R","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_6_8_2","first-page":"1845","article-title":"Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III\/IV) non\u2010Hodgkin\u2019s lymphoma","volume":"22","author":"Tsavaris N","year":"2002","journal-title":"Anticancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400013688"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600799946"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm090"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11593"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06682.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0133"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10879"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.6.727"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.9.1144"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6396"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2471"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054601"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl477"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.12.1475"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.001"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_26_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 3. Available athttp:\/\/www.fda.gov\/cder\/cancer\/toxicityframe.htm(last accessed date 9 August 2006)."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701618250"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152850"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.044"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2006.00544.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500399698"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.093"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07523.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06684.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0360"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802258923"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1997.tb01318.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.9.1139"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1520"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2004.00057.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.11.1343"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70112-U"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1175"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.398"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809057618"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1993.tb03827.x"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00855-7"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00414.x"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000815)89:4<913::AID-CNCR26>3.0.CO;2-8"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.4.504"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01197.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01197.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T20:03:10Z","timestamp":1696968190000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01197.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,27]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01197.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01197.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,27]]}}}